Quantcast

Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets

December 2, 2009

NEW YORK, Dec. 2 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Antibiotic Resistance and Antibiotic Technologies: Global Markets

http://www.reportlinker.com/p0166825/Antibiotic-Resistance-and-Antibiotic-Technologies-Global-Markets.html

Provide an in-depth review of the global market for antibiotics resistance and antibiotics technologies

Offer an analysis of antibiotics resistance from an historical vantage point

Measure the current global market for antibiotics resistance and antibiotics technologies and provide market data for 2008, estimates for 2009, and compound annual growth rates (CAGRs) through 2014

Describe various products by classes, including penicillins and cephalsporins

Profile key players in the antibiotics market

Looks at government regulations adopted in various markets to combat antibiotics resistance.

Chapter- 1: INTRODUCTION — Complimentary

STUDY GOAL AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 2

INTENDED AUDIENCE 2

SCOPE OF REPORT 3

INFORMATION SOURCES AND METHODOLOGY 3

ANALYST’S CREDENTIALS 4

RELATED BCC RESEARCH REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 5

Chapter-2: EXECUTIVE SUMMARY

EXECUTIVE SUMMARY 6

SUMMARY TABLE CURRENT ANTIBIOTICS AND NEW PRODUCTS IN THE GLOBAL MARKET, THROUGH 2014 ($ BILLIONS) 7

SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY PRODUCT CLASSES, 2009 (%) 7

Chapter-3: OVERVIEW

MICROBIOLOGY OF INFECTION 8

ANTIBIOTICS AND THE PROBLEM OF ANTIBIOTIC RESISTANCE 8

TABLE 1 ANTIBIOTIC DISCOVERY AND RESISTANCE DEVELOPMENT 9

BACTERIA: CLASSIFICATION, IDENTIFICATION, AND RESISTANCE STATUS OF VARIOUS CLASSES 9

GRAM POSITIVE BACTERIA 10

Bacillus Anthracis 10

Clostridium 10

C. Botulinum 10

C. Difficle 11

C. Perfringens 11

C. Tetani 11

Corynebacterium Diphtheriae 11

Enterococci 12

Erysipelothrix Rhusiopathiae 12

Nocardia Asteroides 12

Pneumococcus 13

Staphylococcus 13

Streptococcus 14

GRAM-NEGATIVE BACTERIA 14

Bordetella Pertussis 15

Brucella 15

Campylobacter 15

Enterobacteriaceae 16

Cedecea 16

Citrobacter 16

Enterobacter 16

Escherichia coli 16

Klebsiella 17

Salmonella 17

Shigella 17

Haemophilus 18

Neisseria 18

Vibrio cholerae 19

MYCOBACTERIA 19

Mycobacterium Tuberculosis 20

TABLE 2 U.S. TUBERCULOSIS CASES AND DEATHS, 1998-2007 20

Mycobacterium Leprae 21

Mycobacteria other than Tuberculosis (MOTT) 21

SPIROCHETES 21

Borrelia Burgdorferi 22

Treponema Pallidum 22

PATHOGEN DISEASE DISTRIBUTION 22

TABLE 3 ESTIMATED DISEASE INCIDENCE BY BACTERIA IN SELECTED COUNTRIES, 2007 22

COMPARISON OF NOCOSOMIAL AND COMMUNITY INFECTIONS 23

Hospital-Acquired (HA)-MRSA 23

Community-Associated (CA)-MRSA 23

NATURAL DEFENSES PRESENT IN THE COMBAT OF INFECTION 24

ANTISEPTICS 24

BACTERIA AND OTHER MICROORGANISMS OF THE DIGESTIVE TRACT 25

CLASSIFICATION OF ANTIBIOTICS 25

BACTERICIDAL AND BACTERIOSTATIC 26

CLASSIFICATION BASED ON STRUCTURE 26

Penicillins 26

Cephalosporins 27

Fluoroquinolones 27

Tetracyclines 28

Macrolides 28

TABLE 4 COMMONLY USED ANTIBIOTICS BY CLASS 29

CLASSIFICATION BASED ON THE MODE OF ACTION OF ANTIBIOTICS 29

Cell Wall Inhibitors 29

Cell Membrane Inhibitors 30

Nucleic Acid Inhibitors 30

Protein Synthesis Inhibitors 30

TABLE 5 COMMONLY USED PROTEIN SYNTHESIS INHIBITORS 31

Metabolic Inhibitors 31

Fatty Acid Biosynthesis (Fab) Inhibitors 31

ADMINISTRATION OF ANTIBIOTICS 32

DETERMINING THE POTENCY OF ANTIBIOTICS 32

ANTIBIOTIC SUSCEPTIBILITY TESTING 32

DRUG RESISTANCE: THE GREATEST CHALLENGE FACING THE ANTI-INFECTIVE DRUG MARKET 33

THE HISTORY OF ANTIBIOTIC RESISTANCE 33

CURRENT CRISIS OF ANTIBIOTIC RESISTANCE 34

THE MICROBIOLOGY OF ANTIBIOTIC RESISTANCE 34

MECHANISMS OF RESISTANCE DEVELOPED BY VARIOUS BACTERIA 35

Enzymatic Deactivation or Modification of Antibiotic 35

ESBL-Producing Organisms 35

Alteration of the Target Site of the Antibiotic 36

Alteration of the Metabolic Pathways 36

Reducing the Potential for Drug Accumulation 36

Biofilm Formation 37

TABLE 6 HUMAN INFECTIONS INVOLVING BIOFILMS 37

RESISTANCE IN GRAM-POSITIVE BACTERIA 37

Methicillin-Resistant Staphylococcus Aureus (MRSA) 38

Vancomycin-Intermediate S. aureus (VISA) 38

Vancomycin-Resistant Enterococci (VRE) 38

Multi-Drug-Resistant Clostridium difficile 39

RESISTANCE IN GRAM-NEGATIVE BACTERIA 39

Multi-Drug-Resistant Acinetobacter Baumannii 40

Enterobacteriacae- (Resistance by ESBL and AmpC-beta Lactamase Production) 41

Resistance in Pseudomonas Aeruginosa 42

Tetracycline-Resistant, Penicillin-Resistant Neisseria gonorrhoeae 42

ANTIBIOTIC RESISTANCE IN MYCOBACTERIUM 42

TABLE 7 MECHANISMS OF RESISTANCE BY BACTERIA REPORTED AGAINST VARIOUS ANTIBIOTIC CLASSES 43

COST OF ANTIBIOTIC RESISTANCE 43

TABLE 8 ECONOMIC PRESSURES DUE TO ANTIBIOTIC RESISTANCE, INSTITUTIONAL AND SOCIETAL 44

EFFECTS OF INCREASING ANTIBIOTIC RESISTANCE 44

TABLE 9 TREATMENT OPTIONS FOR RESISTANT BACTERIA 45

TABLE 9 (CONTINUED) 46

ANTIBIOTIC STEWARDSHIP PROGRAMS IN HOSPITALS 46

TABLE 10 ESSENTIAL COMPONENTS OF ANTIMICROBIAL STEWARDSHIP PROGRAMS 47

TRENDS IN GEOGRAPHIC DISTRIBUTION OF RESISTANCE 47

Europe 48

U.S. 48

TABLE 11 U.S. ANTIBIOTIC RESISTANCE TRENDS OF SOME CRITICAL INFECTIONS 48

TABLE 11 (CONTINUED) 49

Global Epidemiology Trends of Antibiotic Resistance: Rest of the World 49

TABLE 12 REST OF THE WORLD EPIDEMIOLOGY TRENDS OF ANTIBIOTIC RESISTANCE 50

Chapter-4: REGULATORY TRENDS

POLITICS OF BACTERIAL RESISTANCE 51

AGRICULTURAL ANTIBIOTICS: REGULATORY TRENDS 51

TABLE 13 U.S.-APPROVED AGRICULTURAL ANTIMICROBIALS 51

TABLE 14 AGRICULTURAL ANTIBIOTICS THAT CAN CROSS-SELECT ANTIBIOTICS USED TO TREAT HUMANS 52

TABLE 15 COMMON ANTIBIOTICS IN USE IN LIVESTOCK AND HUMANS 53

REGULATORY ACTIONS AGAINST LARGE-SCALE USE OF AVOPARCIN 54

TABLE 16 REGULATORY ACTIONS TAKEN BY GOVERNMENTS TO CONTROL AGRICULTURAL USE OF AVOPARCIN 55

PREVALENCE OF FLUOROQUINOLONE RESISTANCE DUE TO AGRICULTURAL USAGE 55

TABLE 17 FLUOROQUINOLONES USED IN AGRICULTURE 56

TABLE 18 U.S. REGULATORY ACTIONS CONTROLLING AGRICULTURAL USE OF FLUOROQUINOLONES 56

INTERNATIONAL EFFORTS TO ADDRESS MICROBIAL RESISTANCE 57

ACTION ON ANTIBIOTIC RESISTANCE (REACT) 57

ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS (APUA) 57

EFFORTS BY THE WORLD HEALTH ORGANIZATION (WHO) 57

TABLE 19 ANTIBIOTICS OF CRITICAL IMPORTANCE TO HUMAN MEDICINES CATEGORIZATION BY THE WORLD HEALTH ORGANIZATION 58

REGULATORY TRENDS IN U.S. 58

TABLE 20 U.S. REGULATORY BODIES AND OTHER AGENCIES INVOLVED IN MONITORING AGRICULTURAL ANTIBIOTICS 59

Role of the FDA 59

Impact of Regulations on Innovation 60

EFFORTS BY EUROPEAN REGULATORY AGENCIES 60

European Centre for Disease Prevention and Control (ECDC) 60

European Food Safety Authority (EFSA) 61

TABLE 21 E.U. KEY INITIATIVES TOWARD CONTAINING ANTIBIOTIC RESISTANCE 61

TABLE 22 PROJECTS UNDER DG-SANCO ADDRESSING ANTIBIOTIC RESISTANCE 62

TABLE 22 (CONTINUED) 63

REGULATORY TRENDS IN ASIA 63

Australia 64

China 64

India 64

Japan 65

South Korea 65

Taiwan 65

Taiwan (Continued) 66

Chapter-5: PRODUCTS

PRODUCTS TARGETED AT ANTIBIOTIC RESISTANCE 67

TABLE 23 KEY PRODUCTS TARGETING ANTIBIOTIC RESISTANCE 67

LEVAQUIN 68

ZOSYN/TAZOCIN 68

AVELOX 68

CUBICIN 68

ANTIBACTERIAL DRUGS IN DEVELOPMENT BY CLASS OF PRODUCT 69

BETA LACTAM ANTIBIOTICS 69

TABLE 24 ?-LACTAM ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED 69

Doripenem 70

Tomopenem 70

PZ-601 70

Faropenem 71

Ceftaroline 71

Ceftobiprole 71

BAL-30072 72

FR-264205 72

TABLE 25 ?-LACTAM ANTIBIOTICS, IN DEVELOPMENT OR RECENTLY MARKETED 72

TABLE 25 (CONTINUED) 73

FLUOROQUINOLONES 73

TABLE 26 FLUOROQUINOLONE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED 74

Sitafloxacin 74

Garenoxacin 74

Delafloxacin 74

WCK-771 75

Zabofloxacin 75

DC-159a 75

GLYCOPEPTIDES 75

TABLE 27 GLYCOPEPTIDE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED 76

Dalbavancin 76

Oritavancin 77

Telavancin 77

Ramoplanin 77

MACROLIDES 78

TABLE 28 MACROLIDE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED 78

Cethromycin 78

EDP-420 79

Fidaxomicin 79

OXAZOLIDINONES 79

TABLE 29 OXAZOLIDINONE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED 80

Radezolid 80

Torezolid 80

OTHER CLASSES OF ANTIBIOTICS IN PIPELINE 81

TABLE 30 EMERGING CLASSES OF ANTIBIOTICS 81

TABLE 31 OTHER CLASSES OF ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED 81

TABLE 31 (CONTINUED) 82

TABLE 31 (CONTINUED) 83

Iclaprim 83

PTK 0796 84

AFN-1252 84

Friulimicin 84

Rifalazil 84

Pagibaximab 85

Nemonoxacin 85

Platensimycin 85

NXL-103 85

BC-3205 and BC-3781 86

PMX-30063 86

KBPA-101 86

KB-001 87

ACHN-490 87

CB-182804 87

VACCINES 87

TABLE 32 VACCINES AGAINST BACTERIAL INFECTIONS IN DEVELOPMENT OR NEWLY INTRODUCED 88

Menveo 88

Prevnar 13vPnC 89

Synflorix 89

V710 89

IC43 90

Chapter-6: TECHNOLOGY TRENDS AND PATENT ANALYSIS

DECLINING TRENDS OF INNOVATION IN THE DEVELOPMENT OF NEW ANTIBIOTICS 91

TABLE 33 U.S. FDA-APPROVED SYSTEMIC ANTIBACTERIAL NMES, 1983-2008 91

BROAD-SPECTRUM VERSUS NARROW-SPECTRUM ANTIBIOTICS 91

TABLE 34 SYSTEMIC ANTIBIOTICS TARGETING MRSA IN CLINICAL DEVELOPMENT 92

TABLE 34 (CONTINUED) 93

TABLE 35 ANTIBACTERIALS AGAINST MDR-GRAM-NEGATIVE BACTERIA IN CLINICAL DEVELOPMENT 93

TABLE 35 (CONTINUED) 94

NEW FOCUS ON GRAM-NEGATIVE PATHOGENS 94

ANALOGUES OF EXISTING ANTIBIOTICS VS NOVEL MOLECULES/ TARGETS 95

TABLE 36 ANALOGUES OF EXISTING DRUGS AND NEW MOLECULES 95

CATIONIC PEPTIDES AS NEW GENERATION ANTIBACTERIALS FOR THERAPEUTIC USE 96

TABLE 37 COMPARISON OF CATIONIC PEPTIDE ANTIBIOTICS AND CONVENTIONAL ANTIBIOTICS 96

TABLE 38 CATIONIC ANTIBACTERIAL PEPTIDES FOR SYSTEMIC ADMINISTRATION, UNDER DEVELOPMENT 97

BACTERIAL INTERFERENCE: A NEW APPROACH FOR THE TREATMENT OF BACTERIAL INFECTIONS 97

BACTERIOPHAGE THERAPY 98

PATENT ANALYSIS 98

TABLE 39 U.S. PTO-GRANTED PATENTS BY ANTIBIOTIC STRUCTURAL CLASSES, 1976-SEPTEMBER 8, 2009 99

TABLE 40 TRENDS IN PATENTING OF BIG PHARMA COMPANIES RELATED TO ANTIBIOTICS* 100

TABLE 41 PATENTS IN ANTIBIOTICS BY NEW AND EMERGING COMPANIES, 1976-SEPTEMBER 8, 2009 100

TABLE 41 (CONTINUED) 101

Chapter-7: INDUSTRY STRUCTURE

REVIVAL OF ANTIBIOTIC SECTOR 102

RISING PRESENCE OF BIOTECH COMPANIES 102

TABLE 42 SELECTED BIOTECH ANTIBACTERIALS IN DEVELOPMENT 102

TABLE 42 (CONTINUED) 103

REVIVAL OF THE SECTOR WITH RENEWED INTEREST OF BIG PHARMA 103

TABLE 43 RECENT INVESTMENTS OR PARTNERSHIPS BY BIG PHARMA COMPANIES TARGETING THE ANTIBIOTICS SECTOR 103

TABLE 43 (CONTINUED) 104

GLOBAL MARKET FOR ANTIBIOTICS AND FORECASTS 104

TABLE 44 GLOBAL GROWTH TRENDS FOR CARBAPENEM ANTIBIOTICS, THROUGH 2014 ($ MILLIONS) 104

FIGURE 1 GLOBAL GROWTH TRENDS FOR CARBAPENEM ANTIBIOTICS, 2008-2014 ($ MILLIONS) 105

TABLE 45 GLOBAL GROWTH TRENDS FOR CEPHALOSPORIN ANTIBIOTICS, THROUGH 2014 ($ MILLIONS) 105

FIGURE 2 GLOBAL GROWTH TRENDS FOR CEPHALOSPORIN ANTIBIOTICS, 2008-2014 ($ MILLIONS) 106

TABLE 46 GLOBAL GROWTH TRENDS OF MACROLID ANTIBIOTICS, THROUGH 2014 ($ MILLIONS) 106

FIGURE 3 GLOBAL GROWTH TRENDS OF MACROLID ANTIBIOTICS, 2008-2014 ($ MILLIONS) 107

TABLE 47 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS, THROUGH 2014 ($ MILLIONS) 107

FIGURE 4 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS, 2008-2014 ($ MILLIONS) 108

TABLE 48 GLOBAL MARKET FOR FLUOROQUINOLONES, THROUGH 2014 ($ MILLIONS) 108

FIGURE 5 GLOBAL MARKET FOR FLUOROQUINOLONES, 2008-2014 ($ MILLIONS) 109

TABLE 49 GLOBAL MARKET FOR BACTERIAL VACCINES, THROUGH 2014 ($ MILLIONS) 109

FIGURE 6 GLOBAL MARKET FOR BACTERIAL VACCINES, 2008-2014 ($ MILLIONS) 110

TABLE 50 GLOBAL ANTIBIOTIC MARKETS, THROUGH 2014 ($ MILLIONS) 111

FIGURE 7 GLOBAL ANTIBIOTIC MARKETS, 2008-2014 ($ MILLIONS) 111

LEADING COMPANIES IN THE ANTIBIOTICS MARKET 112

TABLE 51 TOP PLAYERS AND KEY PRODUCTS IN THE ANTIBIOTICS MARKET 112

TABLE 51 (CONTINUED) 113

COMPANY PROFILES 113

ACHAOGEN, INC. 113

ADVANCED LIFE SCIENCES 113

AFFINIUM PHARMACEUTICALS 114

ARPIDA, LTD. 115

BASILEA PHARMACEUTICA LTD. 115

BAYER SCHERING PLOUGH AG 116

BIOSYNEXUS INC. 116

CUBIST PHARMACEUTICALS, INC. 116

ENANTA PHARMACEUTICALS 117

GLAXO SMITHKLINE PLC 117

TABLE 52 GSK’S PIPELINE ANTIBIOTICS AND BACTERIAL VACCINE PRODUCTS 118

TABLE 52 (CONTINUED) 119

INTERCELL AG 119

TABLE 53 INTERCELL AG’S ANTI-BACTERIAL PIPELINE PRODUCTS 120

KALOBIOS PHARMACEUTICALS, INC. 120

KENTA BIOTECH LTD. 121

JOHNSON &JOHNSON 121

MERCK & CO. INC. 122

MPEX PHARMACEUTICALS 122

NABRIVA THERAPEUTICS AG 123

NOVABAY PHARMACEUTICALS, INC. 123

NOVARTIS INTERNATIONAL AG 124

TABLE 54 NOVARTIS’ BACTERIAL VACCINE PIPELINE 125

NOVEXEL 125

OPTIMER PHARMACEUTICALS, INC. 126

OSCIENT PHARMACEUTICALS CORPORATION 126

PARATEK PHARMACEUTICALS, INC. 127

PFIZER, INC. 127

POLYMEDIX, INC. 128

REPLIDYNE, INC. 129

RIB-X PHARMACEUTICALS, INC. 129

SANOFI-AVENTIS 130

TABLE 55 SANOFI-AVENTIS’S BACTERIAL VACCINE CANDIDATES 131

TAIGEN BIOTECHNOLOGY CO., LTD. 131

THERAVANCE, INC. 131

TRIUS THERAPEUTICS 132

WYETH PHARMACEUTICALS 132

TABLE 56 WYETH’S ANTIBACTERIAL PIPELINE 133

APPENDIX 134

TABLE 57 ABBREVIATIONS 134

TABLE 57 (CONTINUED) 135

TABLE 57 (CONTINUED) 136

To order this report:

Prescription Drug Industry: Antibiotic Resistance and Antibiotic Technologies: Global Markets

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


Source: newswire



comments powered by Disqus